Dr. Soetomo General Hospital and Airlangga University, Surabaya, Indonesia; Department of Neurosurgery, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
Department of Neurosurgery, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
J Clin Neurosci. 2023 Sep;115:66-70. doi: 10.1016/j.jocn.2023.07.004. Epub 2023 Jul 25.
Early (within 72 h) tumor-related hemorrhage (TRH) after stereotactic radiosurgery (SRS) of brain metastases (BM) has been reported only occasionally. Systematic review of such cases was done.
Literature search was performed through PubMed according to PRISMA guidelines using combination of the following medical subject headings: "hemorrhage," "stereotactic radiosurgery," and "brain metastasis."
In total, 7 case reports and 8 clinical series, which noted early TRH after SRS of BM were identified. Scarce and inconsistent data precluded their precise synthesis and statistical analysis. BM of renal cell carcinoma comprised around one-third of reported cases. In 4 patients with multiple BM, TRH after SRS was noted simultaneously in several irradiated tumors. Considering 17 reported cases overall, in 3 patients TRH occurred during SRS session itself, in 4 within several minutes upon completion of treatment, in 7 within several hours thereafter, and in 3 on the third posttreatment day. Out of 11 reported cases providing detailed outcome, 6 patients died shortly after the ictus, 2 others were severely disabled at discharge, and 3 demonstrated good-to-moderate recovery. Overall, among evaluated series the median rates of early TRH after SRS for BM were 0.8% per patient (range, 0.4 - 1.9%) and 0.3% per tumor (range, 0.05 - 0.8%).
Early TRH is very rare, but potentially life-threatening complication of SRS for BM; thus, its risk (while extremely low) and possible consequences should be discussed at the time of obtaining informed consent.
立体定向放射外科(SRS)治疗脑转移瘤(BM)后早期(72 小时内)肿瘤相关出血(TRH)的报道很少见。我们对这种病例进行了系统回顾。
根据 PRISMA 指南,通过 PubMed 进行文献检索,使用以下医学主题词的组合:“出血”、“立体定向放射外科”和“脑转移”。
共发现 7 例病例报告和 8 项临床系列研究,这些研究均报道了 SRS 治疗 BM 后早期发生 TRH。由于数据稀少且不一致,无法进行精确的综合和统计分析。报告的病例中,肾细胞癌的 BM 约占三分之一。在 4 例多发性 BM 的患者中,SRS 后同时在几个受照射的肿瘤中发现 TRH。总体而言,在 17 例报告的病例中,3 例在 SRS 治疗过程中发生 TRH,4 例在治疗结束后几分钟内发生,7 例在之后数小时内发生,3 例在治疗后第 3 天发生。在提供详细结局的 11 例报告病例中,6 例患者在出血后不久死亡,2 例患者出院时严重残疾,3 例患者恢复良好至中度。总体而言,在所评估的系列中,SRS 治疗 BM 后早期 TRH 的中位发生率为每位患者 0.8%(范围 0.4-1.9%)和每例肿瘤 0.3%(范围 0.05-0.8%)。
早期 TRH 是 SRS 治疗 BM 后一种非常罕见但潜在危及生命的并发症;因此,应在获得知情同意时讨论其风险(虽然极低)及其可能的后果。